MISSISSAUGA, ON, Nov. 28, 2017 /CNW/ - Nuvo Pharmaceuticals Inc.
(Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF), a commercial
healthcare company with a portfolio of commercial products and
pharmaceutical manufacturing capabilities, today announced that
effective immediately, the Company's common shares will commence
trading on the OTCQX® market in the United States under the symbol "NRIFF".
Nuvo's common shares will continue to trade on the Toronto
Stock Exchange under the symbol "NRI".
"The OTCQX® market will provide our current and
future shareholder base with increased visibility and transparency
through high-quality disclosure, transparent trading and ease of
access to Company information. We appreciate that some
investors prefer to trade in U.S. dollars and upgrading to the
OTCQX® will facilitate this trading," stated
Jesse Ledger, Nuvo's President and
CEO.
U.S. investors can find current financial disclosures and
Real-Time level 2 quotes for the Company on www.otcmarkets.com.
"Nuvo joins over 100 Canadian companies together representing
$30 billion in market capitalization
that cross-trade their shares on our OTCQX Best Market," said
Jason Paltrowitz, Executive Vice
President of OTC Markets Group. "OTCQX enables international
companies to efficiently provide U.S. investors with transparent
trading and convenient access to their news and financials.
We look forward to supporting Nuvo in the U.S. public
market."
About OTC Markets Group Inc.
OTC Markets Group Inc.
(OTCQX: OTCM) operates the OTCQX® Best Market, the
OTCQB® Venture Market, and the Pink® Open
Market for 10,000 U.S. and global securities. Through OTC
Link® ATS, they connect a diverse network of
broker-dealers that provide liquidity and execution services.
They enable investors to easily trade through the broker of their
choice and empower companies to improve the quality of information
available for investors.
About Nuvo Pharmaceuticals Inc.
Nuvo (TSX: NRI; OTCQX:
NRIFF) is a commercial healthcare company with a portfolio of
commercial products and pharmaceutical manufacturing
capabilities. Nuvo has three commercial products that are
available in a number of countries; Pennsaid 2%, Pennsaid and the
heated lidocaine/tetracaine patch. Pennsaid 2% is sold
in the U.S. by Horizon Pharma plc (NASDAQ: HZNP) and is available
for partnering in certain other territories around the world.
Nuvo manufactures Pennsaid for the global market and Pennsaid 2%
for the U.S. market at its FDA, Health Canada and E.U. approved
manufacturing facility in Varennes, Québec. For additional
information, please visit www.nuvopharmaceuticals.com.
Forward-Looking Statements
This Press Release
contains "forward-looking statements" within the meaning of
applicable securities laws. Forward-looking statements can be
identified by words such as: "anticipate," "intend," "plan,"
"goal," "seek," "believe," "project," "estimate," "expect,"
"strategy," "future," "likely," "may," "should," "will" and similar
references to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
the Company's current beliefs, expectations and assumptions
regarding the future of its business, future plans and strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of the Company's control. Nuvo's actual results
and financial condition may differ materially from those indicated
in the forward-looking statements. Therefore, readers should not
rely on any of these forward-looking statements. Important factors
that could cause Nuvo's actual results and financial condition to
differ materially from those indicated in the forward-looking
statements include, among others, the risk factors included in
Nuvo's most recent Annual Information Form dated March 1, 2017 under the heading "Risks Factors",
and as described from time to time in the reports and disclosure
documents filed by Nuvo with Canadian securities regulatory
agencies and commissions. These and other factors should be
considered carefully and readers should not place undue reliance on
Nuvo's forward-looking statements. As a result of the foregoing and
other factors, no assurance can be given as to any such future
results, levels of activity or achievements and none of Nuvo or any
other person assumes responsibility for the accuracy and
completeness of these forward-looking statements.
Any forward-looking statement made by the Company in this
Press Release is based only on information currently available to
it and speaks only as of the date on which it is made. Except as
required by applicable securities laws, Nuvo undertakes no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
SOURCE Nuvo Pharmaceuticals Inc.